209 related articles for article (PubMed ID: 38492769)
1. Engineered bacteria in tumor immunotherapy.
Chen H; Zhu Y; Zhang C; Hu L; Yang K
Cancer Lett; 2024 May; 589():216817. PubMed ID: 38492769
[TBL] [Abstract][Full Text] [Related]
2. Ultrasound-controllable engineered bacteria for cancer immunotherapy.
Abedi MH; Yao MS; Mittelstein DR; Bar-Zion A; Swift MB; Lee-Gosselin A; Barturen-Larrea P; Buss MT; Shapiro MG
Nat Commun; 2022 Mar; 13(1):1585. PubMed ID: 35332124
[TBL] [Abstract][Full Text] [Related]
3. Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy.
Chen J; Li T; Liang J; Huang Q; Huang JD; Ke Y; Sun H
Biomed Pharmacother; 2022 Jan; 145():112443. PubMed ID: 34847476
[TBL] [Abstract][Full Text] [Related]
4. Current Status and Future Directions of Bacteria-Based Immunotherapy.
Tang Q; Peng X; Xu B; Zhou X; Chen J; Cheng L
Front Immunol; 2022; 13():911783. PubMed ID: 35757741
[TBL] [Abstract][Full Text] [Related]
5. Progress of engineered bacteria for tumour therapy.
Xia X; Zhang JW; Zhao B; Zhang M; Chen ZR; Zhang BF; Ji YL; Wang X; Xiong WM; Li JW; Lv QL
Int Immunopharmacol; 2024 May; 132():111935. PubMed ID: 38599096
[TBL] [Abstract][Full Text] [Related]
6. Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy.
Zhu B; Yin H; Zhang D; Zhang M; Chao X; Scimeca L; Wu MR
Cell Mol Immunol; 2024 May; 21(5):436-447. PubMed ID: 38605087
[TBL] [Abstract][Full Text] [Related]
7. Bacteria-Based Cancer Immunotherapy.
Huang X; Pan J; Xu F; Shao B; Wang Y; Guo X; Zhou S
Adv Sci (Weinh); 2021 Apr; 8(7):2003572. PubMed ID: 33854892
[TBL] [Abstract][Full Text] [Related]
8. Current advances in bacteria-based cancer immunotherapy.
Guo C; Liu J; Zhang Y
Eur J Immunol; 2024 Feb; 54(2):e2350778. PubMed ID: 38105295
[TBL] [Abstract][Full Text] [Related]
9. Bacteria-based immune therapies for cancer treatment.
Howell LM; Forbes NS
Semin Cancer Biol; 2022 Nov; 86(Pt 2):1163-1178. PubMed ID: 34547442
[TBL] [Abstract][Full Text] [Related]
10. Treating cancer with infection: a review on bacterial cancer therapy.
Wong S; Slavcev RA
Lett Appl Microbiol; 2015 Aug; 61(2):107-12. PubMed ID: 25963599
[TBL] [Abstract][Full Text] [Related]
11. Bacteria and cancer: Different sides of the same coin.
Laliani G; Ghasemian Sorboni S; Lari R; Yaghoubi A; Soleimanpour S; Khazaei M; Hasanian SM; Avan A
Life Sci; 2020 Apr; 246():117398. PubMed ID: 32032647
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in the Development of Membrane-derived Vesicles for Cancer Immunotherapy.
Xiao Y; Wu M; Xue C; Wang Y
Curr Drug Deliv; 2024; 21(3):403-420. PubMed ID: 37143265
[TBL] [Abstract][Full Text] [Related]
13. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
14. Engineered drug-loaded cells and cell derivatives as a delivery platform for cancer immunotherapy.
Wang L; Liu J
Biomater Sci; 2021 Feb; 9(4):1104-1116. PubMed ID: 33201163
[TBL] [Abstract][Full Text] [Related]
15. Genetically engineered bacteria: a new frontier in targeted drug delivery.
Fooladi S; Rabiee N; Iravani S
J Mater Chem B; 2023 Nov; 11(42):10072-10087. PubMed ID: 37873584
[TBL] [Abstract][Full Text] [Related]
16. Bacteria and bacterial derivatives as delivery carriers for immunotherapy.
Kang SR; Nguyen DH; Yoo SW; Min JJ
Adv Drug Deliv Rev; 2022 Feb; 181():114085. PubMed ID: 34933064
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
[TBL] [Abstract][Full Text] [Related]
18. Tumour-targeting bacteria engineered to fight cancer.
Zhou S; Gravekamp C; Bermudes D; Liu K
Nat Rev Cancer; 2018 Dec; 18(12):727-743. PubMed ID: 30405213
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy to get on point with base editing.
Harbottle JA
Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells at the forefront of cancer immunotherapy with immune potency, genetic engineering, and nanotechnology.
Pan W; Tao T; Qiu Y; Zhu X; Zhou X
Crit Rev Oncol Hematol; 2024 Jan; 193():104231. PubMed ID: 38070841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
